More News

1 August 2024

Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.

30 July 2024

Boehringer Ingelheim secures novel immune checkpoint inhibitor with acquisition of Nerio Therapeutics

29 July 2024

GSK and Flagship Pioneering partner to discover novel medicines and vaccines

24 July 2024

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

22 July 2024

GC Cell and Lukas Announce Strategic Cooperation Agreement to Jointly Tap into the Innovative Cell Therapy including and beyond Korean and Taiwanese Market

22 July 2024

Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy

15 July 2024

Nona Biosciences Enters into Collaboration Agreement with Alaya.bio to Advance CAR-T Cell Therapy

9 July 2024

Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

8 July 2024

Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery

4 July 2024

Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline

4 July 2024

Pentixapharm Acquires Target Discovery Business of Glycotope

1 July 2024

Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

27 June 2024

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

26 June 2024

TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases

25 June 2024

BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio

25 June 2024

Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

19 June 2024

Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases

19 June 2024

Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule Therapeutics for Immunological Diseases

13 June 2024

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease

9 June 2024

GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies

1 June 2024

Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology

30 May 2024

Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

23 May 2024

Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies

21 May 2024

Aktis Oncology enters into strategic collaboration with Lilly to discover and develop novel anticancer radiopharmaceuticals

14 May 2024

NEOsphere Biotechnologies partners with Kymera Therapeutics for Novel Molecular Glue Target Discovery

14 May 2024

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

14 May 2024

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

10 May 2024

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease

30 April 2024

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

29 April 2024

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Adalimumab (Humira) Biosimilars Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Aflibercept (Eylea) Biosimilars Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

CD73 Inhibitor Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

TROP-2-Targeted Immunotherapy Pipeline Review

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Mesothelin-Targeted Immunotherapy Pipeline Review